Deutsche Bank’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Deutsche Bank’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,843	Closed	-$11K	–	5497
2019 Q2	$11K	Sell	1,843 -6,718	-78%	-$25.6K	﹤0.01%	4968
2019 Q1	$29K	Sell	8,561 -141,764	-94%	-$769K	﹤0.01%	4720
2018 Q4	$595K	Buy	150,325 +134,560	+854%	+$1.72M	﹤0.01%	3216
2018 Q3	$311K	Buy	15,765 +7,808	+98%	+$197K	﹤0.01%	4029
2018 Q2	$253K	Sell	7,957 -4,437	-36%	-$160K	﹤0.01%	4179
2018 Q1	$458K	Sell	12,394 -6,156	-33%	-$405K	﹤0.01%	3761
2017 Q4	$1.46M	Buy	+18,550	New	+$1.37M	﹤0.01%	2947

Other funds holding MLNT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Deutsche Bank's MLNT Position: Q3 2019 in Review

Deutsche Bank sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2019, closing a stake of 1,843 shares — an estimated $11K sold.

Deutsche Bank first reported a position in MLNT in Q4 2017 and held it in 7 quarters. The position peaked at $1.46M in Q4 2017. 47 funds tracked by Wall St. Rank hold MLNT as of Q3 2019.

Deutsche Bank reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Deutsche Bank sold 1,843 Melinta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $11K.
Deutsche Bank first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
Deutsche Bank's Melinta Therapeutics, Inc. Common Stock position peaked at $1.46M in Q4 2017.
47 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Deutsche Bank's 13F filing for Q3 2019, filed 14 Nov 2019.